Safety and immunogenicity of a monovalent MF59 ®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults

Biologicals

Volumn 40, Issue 2, 2012, Pages 134-139

  Palma, Paolo ^a   Romiti, Maria Luisa ^b   Bernardi, Stefania ^a   Pontrelli, Giuseppe ^a   Mora, Nadia ^b   Santilli, Veronica ^b   Tchidjou, Hyppolite Kuekou ^b   Aquilani, Angela ^b   Cotugno, Nicola ^b   Alghisi, Federico ^a   Lucidi, Vincenzina ^a   Rossi, Paolo ^a   Douagi, Iyadh ^c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

H1N1; HIV; MF59; Pandemic influenza; Pediatric

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMAGGLUTINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; SKIN REDNESS; SORE THROAT; SWELLING; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; PROSPECTIVE STUDIES; SAFETY; SQUALENE; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858069769     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.12.001     Document Type: Article

References (31)

1. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 27(340):c2649.
2. Faruqui F., Mukundan D. 2009 pandemic influenza: a review. Curr Opin Pediatr 2010, 22:530-535.
3. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
4. Kumar D., Michaels M.G., Morris M.I., Green M., Avery R.K., Liu C., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010, 10:521-526.
5. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
6. Italian Ministry of Health. Ministero della Salute. Nuova influenza. Last accessed 25th July 2011. http://www.nuovainfluenza.salute.gov.it/nuovainfluenza/nuovaInfluenza.jsp.
7. Couch R.B., Kasel J.A. Immunity to influenza in man. Ann Rev Microbiol 1983, 37:529-549.
8. Moir S., Fauci A.S. B cells in HIV infection and disease. Nat Rev Immunol 2009, 9:235-245.
9. Pensieroso S., Cagigi A., Palma P., Nilsson A., Capponi C., Freda E., et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009, 106:7939-7944.
10. Sutcliffe C.G., Moss W.J. Do children infected with HIV receiving HAART need to be revaccinated?. Lancet Infect Dis 2010, 10:630-642.
11. Gasparini R., Schioppa F., Lattanzi M., Barone M., Casula D., Pellegrini M., et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010, 64:432-438.
12. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novelsplit virion, adjuvanted pandemic H1N1Influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52:122-127.
13. Viganò A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. Acquir Immune Defic Syndr 2008, 48:289-296.
14. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
15. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
16. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24:2187-2192.
17. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
18. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
19. Meier S., Bel M., L'huillier A., Crisinel P.A., Combescure C., Kaiser L., et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011.
20. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
21. Oh C.E., Lee J., Kang J.H., Hong Y.J., Kim Y.K., Cheong H.J., et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010, 28:5857-5863.
22. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010, 362:370-372.
23. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
24. Crum-Cianflone N.F., Iverson E., Defang G., Blair P.J., Eberly L.E., Maguire J., et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011.
25. Iorio A.M., Francisci D., Camilloni B., Stagni G., De Martino M., Toneatto D., et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003, 21:3629-3637.
26. Moir S., Buckner C.M., Ho J., Wang W., Chen J., Waldner A.J., et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010, 116:5571-5579.
27. Evison J., Farese S., Seitz M., Uehlinger D., Furrer H., Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.
28. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167-173.
29. Cagigi A., Palma P., Nilsson A., Di Cesare S., Pensieroso S., Kakoulidou M., et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS 2010, 24:2075-2080.
30. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. Clin Invest 2010, 120:1663-1673.
31. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M. MF59 adjuvant enhances diversity affinity antibody-mediated immune response pandemic influenza vaccines. Sci Transl Med 2011, 3(85):48.